Go to deals
Healthcare

LDI has sold UltiMed to Levine Leichtman Capital Partners

UltiMed, Inc., a portfolio company of LDI, Ltd., has been sold to an investment vehicle sub-managed by Levine Leichtman Capital Partners, LLC.

UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease. UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection.

Levine Leichtman Capital Partners is a private equity and venture capital firm specializing in acquisitions, buyouts, recapitalizations, refinancing, balance sheet restructuring, growth financing, structured equity, distressed debt, leveraged loan and mezzanine investments in the middle market.

LDI, Ltd. is a private equity firm specializing in investing in acquisitions and add-on acquisitions. It is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies.

One of Oaklins’ teams in the USA served as the exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in this transaction.

Service
M&A sell-side
Parties
“We selected the team based on their prior experience with UltiMed and their expertise in transactions in the diabetes and animal health sectors. They did an outstanding job of presenting UltiMed’s many strengths and growth opportunities to the market, and their deep relationships with potential acquirors were key to our success. We particularly appreciate the senior team focus they brought to completing this transaction despite the emergence of the COVID-19 pandemic in the midst of this assignment.”

John Martin

VP Corporate Development, LDI, Ltd.

Talk to the deal team

 Michael S. Goldman

Michael S. Goldman

Managing Director
New York, United States
Oaklins TM Capital
 Steve  Hunter

Steve Hunter

Managing Director
Atlanta, United States
Oaklins TM Capital
 James  McLaren

James McLaren

Managing Director
New York, United States
Oaklins TM Capital
 John  Dean

John Dean

Associate Director
Atlanta, United States
Oaklins TM Capital

Related deals

SulAmérica and Rede D’Or São Luiz have announced a combination
Financial Services | Healthcare

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Learn more
Agar Scientific has been acquired by Calibre Scientific
Private Equity | Healthcare

Agar Scientific has been acquired by Calibre Scientific

Agar Scientific Ltd. (Agar) has been sold to Molecular Dimensions Limited, a subsidiary of Calibre Scientific, Inc., a US-based life sciences company, owned by international private investment firm StoneCalibre.

Learn more
Cooper Consumer Health has sold Stardea to EA Pharma
Private Equity | Healthcare

Cooper Consumer Health has sold Stardea to EA Pharma

Cooper Consumer Health has sold Stardea to EA Pharma.

Learn more